Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs

Current Pharmaceutical Design

Volumn 11, Issue 14, 2005, Pages 1779-1793

  Akarca, U S ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Cyclooxygenase; Gastrointestinal complications; Nonsteroidal anti inflammatory drug; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTACID AGENT; ANTICOAGULANT AGENT; ANTIULCER AGENT; AZAPROPAZONE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; KETOROLAC; MELOXICAM; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SUCRALFATE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISEASE; ABDOMINAL PAIN; AGING; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BLEEDING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE PREDISPOSITION; DRUG COST; DRUG MECHANISM; DRUG SELECTIVITY; DYSPEPSIA; ENZYME INHIBITION; EROSION; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEARTBURN; HELICOBACTER PYLORI; HUMAN; IC 50; NAUSEA; OBSTRUCTION; OSTEOARTHRITIS; PATHOGENESIS; PEPTIC ULCER; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STOMACH MUCOSA; STOMACH MUCOSA LESION; STOMACH ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE INHIBITORS; DYSPEPSIA; GASTRIC ACID; GASTROINTESTINAL TRACT; HUMANS; OSTEOARTHRITIS; PEPTIC ULCER; PROSTAGLANDIN ANTAGONISTS;

EID: 18744412968     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764904     Document Type: Review

References (90)

1. Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 2003; 125: 389-395.
2. Rainsford KD, Fox SA, Osborne DJ. Comparative effects of some non-steroidal anti-inflammatory drugs on the ultrastructural integrity and prostaglandin levels in the rat gastric mucosa: relationship to drug uptake. Scand J Gastroenterol Suppl 1984; 101: 55-68.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-5
4. Robert A, Schultz JR, Nezamis JE, Lancaster C. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology 1976; 70: 359-70.
5. Carmichael HA, Nelson L, Chandra V, Lyon A, Cochran KM, Russell RI. Proceedings: Inhibition of aspirin and taurocholic acid-induced gastric mucosal bleeding by prostaglandin 15(R)15 methyl-E2 methyl ester. Gut 1975; 16: 822.
6. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245(5 Pt 1): G601-23.
7. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-42.
8. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 1491-5.
9. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68-69: 165-75.
10. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002; 68-69:95-114.
11. Wallace JL. Pathogenesis of NSAID-induced gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15: 691-703.
12. Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521-35.
13. Holzer P, Michl T, Danzer M, Jocic M, Schicho R, Lippe IT. Surveillance of the gastrointestinal mucosa by sensory neurons. J Physiol Pharmacol 2001; 52(4 Pt 1): 505-21.
14. Gana TJ, Huhlewych R, Koo J. Focal gastric mucosal blood flow in aspirin-induced ulceration. Ann Surg 1987; 205: 399-403.
15. Konturek JW, Dembinski A, Stoll R, Konturek M, Domsehke W. Gastric mucosal blood flow and neutrophil activation in aspirin-induced gastric mucosal damage in man. Scand J Gastroenterol 1993; 28: 767-71.
16. Hogaboam CM, Bissonnette EY, Chin BC, Befus AD, Wallace JL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology 1993; 104: 122-9.
17. Pihan G, Rogers C, Szabo S. Vascular injury in acute gastric mucosal damage. Mediatory role of leukotrienes. Dig Dis Sci 1988; 33: 625-32.
18. Fromm D. How do non-steroidal anti-inflammatory drugs affect gastric mucosal defenses? Clin Invest Med 1987; 10: 251-8.
19. Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of nonsteroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99.
20. Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823-57.
21. Livingston EH. Acid diffusion through rat duodenal mucosal cap. Dig Dis Sci 2002; 47: 974-7.
22. Konturek JW, Hengst K, Konturek SJ, Domschke W. Epidermal growth factor in gastric ulcer healing by nocloprost, a stable prostaglandin E2 derivative. Scand J Gastroenterol. 1997; 32: 980-4.
23. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994; 39: 362-5.
24. Chan FK, Sung JJ. Role of acid suppressants in prophylaxis of NSAID damage. Best Pract Res Clin Gastroenterol 2001; 15: 433-45.
25. Aalykke C, Lauritsen JM, Hallas J, Reinholdt S, Krogfelt K, Lauritsen K. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: a case-control study. Gastroenterology 1999; 116: 1305-9.
26. Bazzoli F, De Luca L. Helicobacter pylori infection and the use of NSAIDs. Best Pract Res Clin Gastroenterol 2001; 15: 775-85.
27. Bassotti G, Bucaneve G, Furno P, Morelli A, Del Favero A. Double-blind, placebo-controlled study on effects of diclofenac sodium and indomethacin on postprandial gastric motility in man. Dig Dis Sci 1998; 43:1172-6.
28. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110 Suppl 3A: 20S-7S.
29. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104 (3A): 23S-29S
30. MacDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology 2000; 39 Suppl 2:13-20
31. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996; 15: 450-6.
32. Bijlsma JW. Treatment of NSAID-induced gastrointestinal lesions with cimetidine: an international multicentre collaborative study. Aliment Pharmacol Ther 1988; 2 Suppl 1: 85-95.
33. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156:1530-6.
34. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8-16.
35. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-91.
36. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32.
37. Whittle BJ. Gastrointestinal effects of nonsteroidal anti-inflammatory drugs. Fundam Clin Pharmacol 2003; 17:301-13.
38. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63.
39. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343 (8900): 769-72.
40. Weil J, Langman MJ, Wainwright P, Lawson DH, Rawlins M, Logan RF, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27-31.
41. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-7.
42. Ofman JJ, Maclean CH, Straus WL, Morton SC, Berger ML, Roth EA, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003; 49: 508-18.
43. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88.
44. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-70.
45. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114:735-740.
46. Gutthann SP, Garcia Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18-24.
47. Henry D, Lira LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6.
48. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol 1999; 26 Suppl 56: 18-24.
49. Rahme E, Joseph L, Kong SX, Watson KJ, LeLorier J. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43:917-924.
50. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003; 25(2 Suppl): S32-40.
51. McCarthy D. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol 2001; 15: 755-773.
52. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1996; 15: 450-6.
53. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996; 156:1530-6.
54. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998; 338: 719-26.
55. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998; 338: 727-34.
56. Croker JR, Cotton PB, Boyle AC, Kinsella P. Cimetidine for peptic ulcer in patients with arthritis. Ann Rheum Dis 1980; 39: 275-8.
57. Davies J, Coltins AJ, Dixon SA. The influence of cimetidine on peptic ulcer in patients with arthritis taking anti-inflammatory drugs. Br J Rheumatol 1986; 25: 54-8.
58. O'Laughlin JC, Silvoso GK, Ivey KJ. Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up. Dig Dis Sci 1982; 27: 976-80.
59. Campbell DR, Haber MM, Sheldon E, Collis C, Lukasik N, Huang B, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. Am J Gastroenterol 2002; 97: 2208-14.
60. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med 1994; 96: 274-81.
61. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017-1021.
62. Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FL, et al. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci 1989; 34: 424-428.
63. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 2: 1277-80.
64. Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 1993; 119: 257-62.
65. Fiorucci S, Dei Soldato P. NO-aspirin: mechanism of action and gastrointestinal safety. Dig Liver Dis 2003; 35 Suppl 2: S9-19.
66. Hawkey CJ, Jackson L, Harper SE, Simon TJ, Mortensen E, Lines CR. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001; 15: 1-9.
67. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, et al. Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone:] a potent and orally active cyclooxy-genase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290:551-60.
68. Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 201-6.
69. Lanza FL, Rack MF, Simon TJ, Quan H, Bolognese JA, Hoover ME, et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 1999; 13: 761-7.
70. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-83.
71. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000; 43: 370-7.
72. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001; 15: 1593-601.
73. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
74. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354: 2106-11.
75. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-33.
76. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
77. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
78. Singh G, Goldstein J, Bensen W, Agrawal N, Eisen G, Fort J, et al. Success-1 in osteoarthritis (OA) trial: celecoxib significantly reduces the risk of serious upper GI complications compared to NSAIDs while providing similar efficacy in 13,274 randomized patients. Ann Rheum Dis 2001; 60 (Suppl 1): 58.
79. Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795-806.
80. Tacconelli S, Capone ML, Patrignani P. Clinical Pharmacology of Novel Selective COX-2 Inhibitors. Curr Pharm Des 2004; 10: 589-601.
81. Joshi GP, Viscusi ER, Gan TJ, Minkowitz H, Cippolle M, Schuller R, et al. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. Anesth Analg. 2004; 98: 336-42.
82. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 2003; 3: 1.
83. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther 2003; 18: 125-32.
84. Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology 2003; 42: 1207-15.
85. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidente of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14:1101-11.
86. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 530-7.
87. Leese PT, Recker DP, Kent JD. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J Clin Pharmacol 2003; 43: 504-13.
88. Lanas A, Panes J, Pique JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Design 2003; 9(27): 2253-66.
89. Scheiman JM. Gastroduodenal safety of cyclooxygenase-2 inhibitors. Curr Pharm Design 2003; 9(27): 2197-206.
90. Thompson AJ, Yeomans ND. COX-2 inhibition versus gastroprotection with dual COX inhibitors: an evidence-based approach. Curr Pharm Design 2003; 9(27): 2221-8.